在一只猫中,心力衰竭与米诺克西迪尔中毒相关
1ADVETIA Veterinary Hospital, 9 Avenue Louis Breguet, 78140, Vélizy-Villacoublay, France.
概括
猫对米诺西迪尔的暴露可能会导致暂时的心脏问题,包括充血性心力衰竭和心肌缩. 及时治疗可以导致完全康复,但如果暴露持续下去,复发是可能的.
科学领域:
- 兽医心脏病学 兽医心脏病学
- 毒理学 毒理学 毒理学
背景情况:
- 猫的充血性心力衰竭 (CHF) 可以呈现出各种原因.
- 心肌缩和心房扩张是猫类心脏病中心声图的关键发现.
研究的目的:
- 报告一只猫的复发性充血性心力衰竭病例.
- 调查过渡性心肌功能障碍的潜在环境原因.
主要方法:
- 临床表现,胸部放射和心声回声被用于诊断.
- 治疗涉及标准的CHF管理,包括furosemide和pimobendan.
- 评估了心脏中托罗邦尼I水平.
主要成果:
- 这只猫经历了两次心血管衰竭,肺和心肌厚.
- 这两次发作都通过医疗管理得到解决,并且与米诺克西迪尔暴露有关.
- 在第二次发作期间,我心脏的热素水平升高.
结论:
- 在出现急性心脏事件的猫群中,应考虑米诺西迪尔中毒.
- 过渡性心肌缩和CHF可能与氧化暴露有关.
- 暴露结束后,完全的心声回复可能会恢复.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
Cardiomyopathy II: Dilated Cardiomyopathy
468
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
468
Myocarditis III: Medical Management
174
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
174
Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338


